Stephen Leong MD
1
Stephen Leong MD May 2011
University of Colorado Cancer Center
Mail Stop 8117
12801 E. 17th Ave Room 8120
Aurora Colorado 80045
PH: (303) 724-3837
Fax: (303) 724-3892
Anschutz Cancer Pavilion
University of Colorado Hospital
1665 Aurora Court
Aurora, CO 80045
Ph: (720) 848-0300
Fax: (720) 848-1411
1
Stephen Leong MD May 2011
Present Position (2007-Present):
Assistant Professor, Medical Oncology
Developmental Therapeutics /GI Malignancies Programs
Director of Oncology Teaching Services
Citizenships: US, Canadian and EU National (Portugal);
Education and Training
2004-2007 University of Colorado Hematology and Medical Oncology Fellowship
Focusing on Gastrointestinal malignancies and Phase 1 clinical trials.
Mentor: S. Gail Eckhardt
2003-2004 Albert Einstein Medical Center, Philadelphia PA- Chief Resident
2000-2003 Albert Einstein Medical Center, Philadelphia PA- Internal Medicine Residency
1998-1999 University College Dublin - Master in Medical Science (MMedSci) Physiology
Royal College of Surgeons in Ireland, Dept of Physiology, Dublin, Ireland
Tutor/ Demonstrator for medical students
Lecturer for undergraduate and graduate nursing students
Research
1997-1998 Internship in Medicine and Surgery.Royal College of Surgeons in Ireland- Beaumont Hospital, Dublin, Ireland- 1997-
1991-1997 Royal College of Surgeons in Ireland- Medical Education
MB BCh BAO LRCP&SI, May 1997
Certification: 2004 - American Board of Internal Medicine
2007 – Medical Oncology
Licenses: 2007 to Present: Colorado License CO45455
2007 to Present: DEA FL0372603
Awards and Honors
2011Scholarship: Harvard Medical School - Program in Palliative Care Education and Practice
2009 NCI K12 Award (Paul Calabresi Clinical Oncology Scholar Award)
2007 University of Colorado Development Therapeutics Poster Award
2006Scholarship ASCO/AACR Workshop. “Methods in Clinical Cancer Research”, Intensive workshop in the essentials of effective clinical trial design for clinical fellows and junior faculty clinical researchers in all subspecialties, including radiation and surgical oncology. Vail, Colorado.
2005 NIH Institutional Ruth L. Kirschstein National Research Service Award (T32)
Medical School
1st class Honors in General Practice
2nd class Honors Grade 1: 3rd year Medicine and Surgery, Psychiatry, Ophthalmology, Pharmacology, Anesthetics, Tropical Medicine, Anatomy, Biology, Biochemistry and Physics
2nd class Honors Grade 2: Physiology, Microbiology and Chemistry
Undergraduate:
1989 - Government of Canadian Scholarship – University of Western Ontario
1988 - Lieutenant Governor General of Ontario Silver Medal
Professional Membership
2006 -PresentAmerican Association of Cancer Research - Associate Member
2004 -2007American Society of Hematology - Associate Member
2005 -PresentAmerican Society of Clinical Oncology - Associate Member
2004 -PresentRocky Mountain Oncology Society
Committees
2011 – PresentSpecial Emphasis Panel for the Review of 2011 Loan Repayment Program at the NCI
2010 – PresentCancer League of Colorado – Scientific Advisor Board
2008 – PresentUniversity of Colorado Dept of Medicine Blueprint for Change Committee
2007 – PresentColorado Medical Institutional Review Board
2007 – PresentUniversity of Colorado Medical Residency Interview Committee
2007 – PresentUniversity of Colorado Hematology / Oncology Fellowship Interview Committee
2005 – PresentUniversity of Colorado Cancer Center - Protocol Review Committee
1995 -1996Royal College of Surgeons in Surgeons in Ireland Student Union – Treasurer
Manuscripts:
1.Leong S, Docherty J. Vascular inhibitory actions of 17β-oestradiol in rat portal vein. Journal of Autonomic Physiology J Auton Pharmacol. 2001 Apr;21(2):95-9.
2.Rajamnai K, Leong S, Lavelle A, Docherty J. Prejunctional actions of methlenedeioxymethamphetamine in vas deferens from wild-type and α 2a/d adrenoceptor knockout mice. Eur J Pharmacol.2001 Jul 6;423(2-3):223-8.
3.Camidge DR, Eckhardt SG, Gore L, O’Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs. 2008 Jan;19(1):77-84.
4.Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, and Eckhardt SG. A Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule MEK1/2 Inhibitor AZD6244 (ARRY-142886) in Patients with Advanced Cancers. J Clin Oncol. 2008 May 1;26(13):2139-46.
5.O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol. 2009 Feb;63(3):477-89.
6.Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, and Raben D. Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation: Report of Toxicity and Evaluation of Circulating K-ras as a Potential Biomarker of Response to Therapy. Am J Clin Oncol. 2009 Apr;32(2):115-21.
7.Leong S, Cohen RB, Dustafson DL, Langar CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O’Bryant C, Hariaharan S, Diab S, Fox NL, Miceli R, Eckhardt SG.Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. J Clin Oncol. 2009 Sep 10;27(26):4413-21.
8.Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR.A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs. 2010 Jan 19.
9.Spratlin JL, Cohen RB, Eadens M, Gore L , Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQM, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, and Eckhardt SG. A Phase I, Pharmacological, and Biological Study of IMC-1121B, aFully-Human IgG1 Monoclonal Antibody, that Targets the Vascular Endothelial Growth Factor Receptor-2. J Clin Oncol. 2010 Feb 10;28(5):780-7.
10.Wood J, Leong S, McCarter M, Pearlman N, Stiegmann G, Gonzalez RJ. Endoscopic-Assisted Closure of Persistent Gastrocutaneous Fistula With a Porcine Fistula Plug: Report of a New Technique. Surg Innov. 2010 Mar;17(1):53-6
11.KurzrockR, Patnaik A, Aisner J, Warren T, Leong S, BenjaminR, Eckhardt SG, EId JE, Greig G, HabbenK,McCarthyCD, GoreL. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor receptor-1 antagonist, in patients with advanced solid tumors. Clin Can Res. 2010 April 15; 16(8):2458-65.
12.Pitts TM, Tan AC, Kulikowski G, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsh FR, Varella-Garcia M, Korch C, Echardt SG. Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development. Clin Cancer Res. 2010 Jun 15;16(12):3193-204.
13.Tentler J, Nallapreddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby H, Kachaeva M, Flanigan S, Kilikowski G, Leong S, Arcaroli J, Messermith WA, Eckhardt SG. Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in KRAS-Mutated Colorectal CancerMol Cancer Ther. 2010 Oct 5.
14.Flanigan SA, Pitts TM, Eckardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S. The IGF-1R/IR Tyrosine Kinase Inhibitor, PQIP, Exhibits Enhanced Anti-Tumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models.Clin Cancer Res. 2010 Oct 13.
Manuscripts submitted / accepted:
1.O’Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugolpal B, Leong S, Boinpally R, Franke A, Witt Karsten, Evans J, Belani C, Eckhardt SG, Ramalingam S. An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib in Patients with Advanced Solid Tumors with Adequate and Moderately Impaired Hepatic Function. Submitted to Molecular Cancer Therapeutics.
2.Thompson C, Leong S, Messersmith WA.Promising Targets and Drugs in Development for Colorectal Cancer. Submitted to Seminars in Oncology.
Reviews and Book Chapters
1.Leong S, Eckhardt SG, Jimeno A, Messersmith WA. The Importance of K-Ras Status in Managing Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 2009, 5:129–134
2.Leong S, Messersmith WA, Tan AC,Eckhardt SG. Novel Agents in the Treatment of Metastatic Colorectal Cancer. Cancer J. 2010 May-Jun;16(3):273-82.
3.Leong S, Messersmith WA, Tan AC, Eckhardt SG Management Strategies for Patients with KRAS Mutations. Curr Colorectal Cancer Rep (2010) 6:199–205
4.Leong S, Call J, Ajeit AA, Messersmith WA. Part III Chapter 1: Phase I Clinical Trials of Anticancer Agents. Principles of Anticancer Drug Development. Editors Hidalgo, M; Garrett-Mayer, E; Clendeninn, N. and Eckhardt SG. Springer Science. 2011
Abstracts / Presentations:
1.Leong S, Walsh J. Clinical Manifestation of Renal Artery Stenosis in Ireland. Poster Presentation – Irish Nephrology Association Annual Meeting 1998
2.Leong S, Docherty JR. Vascular inhibitory actions of 17β-oestradiol in rat portal vein. Oral Presentation at University College Dublin Research Day 1999; Poster Presentation – Royal College of Surgeons in Ireland Research Day 1999
3.Leong S. Effects of Tacrolismus based Immunosuppressive Regimen in High Risk Renal Transplantations Presented at Medical Grand Rounds at Albert Einstein Medical Center, Philadelphia PA April 2001
4.Lieu CH, Leong S, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Boinpally R, Eckhardt SG, O’Bryant CL. 2005. A Dose-Ranging Study of the Toxicities, Pharmacological, and Biological Effects of the Selective Apoptotic Antineoplastic Drug (SAAND), OSI-461, in Patients With Advanced Cancer, in the Fasting and Fed State. Presented at the 2005 AACR-NCI-EORTC Annual Molecular Targets and Cancer Therapeutics Meeting, Nov 2005, Philadelphia, PA.
5.Leong S, Camidge DR, Eckhardt SG, Basche M, Musib L, Baldwin J, Darstein C, Thornton D, Britten C. A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 2048
6.O’Bryant CL, Eckhardt SG, Hariharan S, Leong S, Belani C, Ramanathan R, Boinpally R, Gibbs A, Witt K, Ramalingam S. An Open-Label Study to Characterize the Pharmacokinetic (PK) Parameters of Erlotinib in Patients with Advanced Solid Tumors with Adequate or Moderately Impaired Hepatic Function. Presented at the 2006 AACR-NCI-EORTC Annual Molecular Targets and Cancer Therapeutics Meeting, Nov 2006, Prague, Czech Republic.
7.Leong S, Eckhardt SG, O'Bryant CL, Chow LQ, Hariharan S, Camidge R, Diab S, Maneval EC, Chao R, Lockhart AC. A Phase I Study of Sunitinib in Combination with Modified FOLFOX 6 (mFOLFOX6) Chemotherapy.
- Presented at the 2007 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to the Prevention, Diagnosis, and Therapy of GI Cancers, January 19-21, 2007 Orlando World Center Marriott, Orlando, Florida.
- Presented 2006 World Congress on Gastrointestinal Cancer. June 27-30, Barcelona Spain.
- Presented at ECCO14, Sept 22-27 2007, Barcelona Spain.
8.Flaherty KT, Gore L, Avadhani A, Leong S, Harlacker K, Zhong Z, Johnson RG, Hannah AL, O’Dwyer P, Eckhardt SG. 2007 Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14059
9.Olsen C, Schefter T, Kane M, Leong S, McCarter M, Eckhardt G, McCoy K, Mack P, Chen H, Raben, D. "Phase I Trial Results of Gefitinib, Paclitaxel adn Radiation Therapy in Patients with Locally Advanced Pancreatic Cancer" ASTRO Translational Research in Radiation Oncology and Radiology Meeting, San Francisco, CA, September 7th-8th, 2007.
10.Kaufman SA, Pitts TM, Serkova NJ, Stephens A, Eckhardt SG, Leong S. 2007. In vitro assessment of the IGF1R inhibitor, OSI868, alone and in combination with chemotherapy, against human colorectal cancer cell lines: antiproliferative, molecular, and metabolic effects. Presented at the 2007 AACR-NCI-EORTC Annual Molecular Targets and Cancer Therapeutics Meeting, Nov 2007, San Francisco, CA.
11.O’Bryant CL, Leong S, Camidge DR, Gore L, Diab S, Gustafson DL, Call J, Spratlin J, Zweibel JA, Eckhardt SG. A phase 1 study of Belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma. Presented at the 2007 AACR-NCI-EORTC Annual Molecular Targets and Cancer Therapeutics Meeting, Nov 2007, San Francisco, CA.
12.Duran I, Siu LL, GontovnickL, Lovell S, Leong S,Wang L, Braun C, Borgford T, Eckhardt SG, Gore L. Phase I study of the ribosome inactivating protein TST10088 (TST) in patients with advanced solid tumors. Presented at the 2007 AACR-NCI-EORTC Annual Molecular Targets and Cancer Therapeutics Meeting, Nov 2007, San Francisco, CA.
13.Spratlin JL, Eckhardt SG, Gore L, Camidge DR, Diab S, Leong S, Obryant C, Chow LQM, Youssoufian H, Fox F, amd Cohen RB. A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors. Presented at the 2007 AACR-NCI-EORTC Annual Molecular Targets and Cancer Therapeutics Meeting, Nov 2007, San Francisco, CA.
14.Leong S; Eckhardt SG, Moulder S, Warren T, Gore L, Diab S, Kurman M, Dias C, Greig G, Kurzrock. 2007. A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. Presented at the 2007 AACR-NCI-EORTC Annual Molecular Targets and Cancer Therapeutics Meeting, Nov 2007, San Francisco, CA.
15.Pitts TM, Kaufman SA, Tentler JJ, Leong S, Coldren CC, Hirsch FR, Varella-Garcia M, Eckhardt SG. Development and characterization of predictive markers to the IGF-1R inhibitor, PQIP, in colorectal cancer. Presented at AACR/NCI/EORTC International Conference in Molecular Targets and Cancer Therapeutics, Oct 2008, Geneva, Switzerland.
16.Duran I, Siu LL, Kollmannsberger, Gontovnick L, Leong S, Wang L, Braun C, Borgford, Eckhardt SG, Gore L. Phase I study of the ribosome inactivating protein TST10088 (TST) in patients with advanced solid tumors. Presented at AACR/NCI/EORTC International Conference in Molecular Targets and Cancer Therapeutics, Oct 2008, Geneva, Switzerland.
17.Leong S, O’Bryant CL, Messersmith WA, Diab S, Kane MA, Nallapreddy S, Weekes C, Spratlin J, Call J, Eckhardt SG. A phase I study of Gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignanices. Presented at AACR/NCI/EORTC International Conference in Molecular Targets and Cancer Therapeutics, Oct 2008, Geneva, Switzerland
18.Flanigan SA, Pitts TM, Kulikowski GN, Tan AC, Nallapareddy S, Tentler JJ, Eckhardt SG, Leong S. Rational combination of the IGF-1R/IR tyrosine kinase inhibitor (TKI), OSI-906, with the MEK inhibitor, U0126, results in synergistic and apoptotic effects in human colorectal cancer (CRC) cell lines. Presented at the AACR/NCI/EORTC International Conference in Molecular Targets and Cancer Therapeutics, Oct 2009, Boston MA.
19.Von Mehren M, Britten C, Piesolor P, Balogh K, Bartok A, Harris S, Liu X, Galluppi J, Barton J, Leong S. A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in patients with relapsed or refractory solid tumour. Presented at the ECCO 15th – 34th ESMO Multidisciplinary Congress, Sept 2009. Berlin, Germany. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 128
20.Anthony LB, Loehrer PJ, Leong S, Shah MH, Safran H, Senzer NN, Zojwalla NJ, Youssoufian H.Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma. J Clin Oncol 28:15s, 2010 (suppl; abstr TPS220)
21.Von Mehren M, Britten C, Lear K, Camdige DR, Wainberg ZA, Pieslor PC, Darif M, Harris M, Balogh, Leong S. Phase I A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in solid tumors.J Clin Oncol 28:15s, 2010 (suppl; abstr 2612)
22.Nallapreddy S, Eckhardt SG, O’Bryant CL,Eppers S, Diab S, Kane MA, Weekes CD, Messersmith WA, Leong S.A phase I study of gemcitabine, capecitabine, and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies. J Clin Oncol 28:15s, 2010 (suppl; abstr 2535)
23.Sun W, Nelson D, Alberts SR, Poordad F, Leong S, Teitelbaum UR, Woods L, Fox N, O’Neill BH. Phase IB study of mapatumumab in combination with sorafenib in patients with advanced hepatocelullar carcinoma (HCC) and chronic viral hepatitis. J Clin Oncol 29: 2011 (suppl 4; abstr 261)
1
Stephen Leong MD May 2011